158 related articles for article (PubMed ID: 19618072)
1. The use of serology as an additional tool to support diagnosis of difficult multibacillary leprosy cases: lessons from clinical care.
Oliveira ML; Cavaliére FA; Maceira JM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():27-33. PubMed ID: 19618072
[TBL] [Abstract][Full Text] [Related]
2. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of antibody responses.
Roche PW; Britton WJ; Failbus SS; Williams D; Pradhan HM; Theuvenet WJ
Int J Lepr Other Mycobact Dis; 1990 Sep; 58(3):480-90. PubMed ID: 2205683
[TBL] [Abstract][Full Text] [Related]
3. Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.
Barreto JA; Nogueira ME; Diorio SM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():45-7. PubMed ID: 19618075
[TBL] [Abstract][Full Text] [Related]
4. The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients.
Roche PW; Britton WJ; Neupane KD; Failbus SS; Cho SN; Theuvenet WJ
Am J Trop Med Hyg; 1991 Jun; 44(6):702-8. PubMed ID: 1858971
[TBL] [Abstract][Full Text] [Related]
5. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.
Brito Mde F; Ximenes RA; Gallo ME; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():67-72. PubMed ID: 19618079
[TBL] [Abstract][Full Text] [Related]
6. Borderline Lepromatous Leprosy: Cutaneous Manifestation and Type 1 Reversal Reaction.
Hattori M; Motegi S; Amano H; Ishii N; Ishikawa O
Acta Derm Venereol; 2016 Mar; 96(3):422-3. PubMed ID: 26439279
[No Abstract] [Full Text] [Related]
7. Can anti-PGL-1 and anti-NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?
Devides AC; Rosa PS; de Faria Fernandes Belone A; Coelho NMB; Ura S; Silva EA
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):260-265. PubMed ID: 29669693
[TBL] [Abstract][Full Text] [Related]
8.
Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
Front Immunol; 2018; 9():915. PubMed ID: 29867930
[TBL] [Abstract][Full Text] [Related]
9. Leprosy pseudoimbricata: an unusual presentation of steroid-modified borderline lepromatous leprosy.
Kumar S; Mehta H; Aggarwal D; Chatterjee D; Narang T; Dogra S
Int J Dermatol; 2020 Apr; 59(4):e124-e125. PubMed ID: 31957882
[No Abstract] [Full Text] [Related]
10. Borderline lepromatous leprosy in an Italian man.
Massone C; Clapasson A; Nunzi E
Am J Trop Med Hyg; 2013 Feb; 88(2):211. PubMed ID: 23390219
[No Abstract] [Full Text] [Related]
11. The influence of ML Flow test in leprosy classification.
Grossi MA; Leboeuf MA; Andrade AR; Lyon S; Antunes CM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():34-8. PubMed ID: 19618073
[TBL] [Abstract][Full Text] [Related]
12. IgM anti-phenolic glycolipid-I antibody measurements from skin-smear sites: correlation with venous antibody levels and the bacterial index.
Butlin CR; Soares D; Neupane KD; Failbus SS; Roche PW
Int J Lepr Other Mycobact Dis; 1997 Dec; 65(4):465-8. PubMed ID: 9465156
[TBL] [Abstract][Full Text] [Related]
13. Single lesion borderline lepromatous leprosy.
Ranjan Kar B; Belliappa PR; Ebenezer G; Job CK
Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):45-7. PubMed ID: 15217316
[TBL] [Abstract][Full Text] [Related]
14. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients.
Bührer-Sékula S; Visschedijk J; Grossi MA; Dhakal KP; Namadi AU; Klatser PR; Oskam L
Lepr Rev; 2007 Mar; 78(1):70-9. PubMed ID: 17518099
[TBL] [Abstract][Full Text] [Related]
15. Leprosy serology using PGL-I: a systematic review.
Moura RS; Calado KL; Oliveira ML; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():11-8. PubMed ID: 19618069
[TBL] [Abstract][Full Text] [Related]
16. Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.
Leturiondo AL; Noronha AB; do Nascimento MOO; Ferreira CO; Rodrigues FDC; Moraes MO; Talhari C
BMC Infect Dis; 2019 Jan; 19(1):22. PubMed ID: 30616580
[TBL] [Abstract][Full Text] [Related]
17. Erythema nodosum leprosum presenting as sweet's syndrome-like reaction in a borderline lepromatous leprosy patient.
Suryawati N; Saputra H
Int J Mycobacteriol; 2018; 7(2):191-194. PubMed ID: 29900900
[TBL] [Abstract][Full Text] [Related]
18. Active search for leprosy cases in Midwestern Brazil: a serological evaluation of asymptomatic household contacts before and after prophylaxis with bacillus Calmette-Guérin.
Limeira OM; Gomes CM; Morais OO; Cesetti MV; Alvarez RR
Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740009
[TBL] [Abstract][Full Text] [Related]
19. Serological monitoring of the response to chemotherapy in leprosy patients.
Roche PW; Britton WJ; Failbus SS; Neupane KD; Theuvenet WJ
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):35-43. PubMed ID: 8326179
[TBL] [Abstract][Full Text] [Related]
20. HLA and leprosy in the pre and postgenomic eras.
Geluk A; Ottenhoff TH
Hum Immunol; 2006 Jun; 67(6):439-45. PubMed ID: 16728267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
